Fall Prevention by Alfacalcidol and Training (SPALT)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00483275 |
Recruitment Status
:
Withdrawn
(No final agreement with sponsor)
First Posted
: June 7, 2007
Last Update Posted
: July 21, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Accidental Falls Chronic Renal Insufficiency Aged | Drug: Alfacalcidol Behavioral: Balance, gait and strength training Behavioral: Patient education | Phase 4 |
The risk of falling increases with age. An impaired renal function is an additional risk factor. Guidelines and systematic reviews suggest, that multimodal interventions are most likely to control this risk. This study evaluates, if patients at high risk for falls will benefit from a multimodal intervention simple and feasible enough to be transferred into general practice. Participants will be randomized either into an intervention group or a control group receiving usual care.
The multimodal intervention consists of:
- medication: Participants receive 1µg Alfacalcidol and 500mg Calcium daily
- mobility program: strength, balance and gait training twice a week for one hour
- patient education: a single meeting with teaching lessons on risk factors for falling and modes of fall prevention followed by an evaluation of the individual fall risk and corresponding recommendations to reduce it
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 484 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | Effects of a Multi-modal 12-month-intervention With Alfacalcidol Plus Calcium, Patient Education and a Mobility Program on the Number of Fallers Among Patients With an Impaired Kidney Function Aged 65 and Older. |
Study Start Date : | June 2007 |
Estimated Study Completion Date : | September 2009 |

- Number of fallers [ Time Frame: One year ]
- Number of falls [ Time Frame: One year ]
- Number of fractures [ Time Frame: One year ]
- Performance in balance and mobility [ Time Frame: One year ]
- Fear of falling [ Time Frame: One year ]
- Rate of hypercalcaemia [ Time Frame: One year ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 65 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Men and women who are 65 years of age or older
- Personal history of at least one movement-related, non-syncopal fall, either within the past year OR earlier with additional findings of an increased fall risk during screening examination.
- Creatinine-clearance of 30 to 60 ml/min equivalent to a moderately impaired kidney function (stage 3) according to the classification of the Kidney Disease Outcomes Quality Initiative (K/DOQI) of the National Kidney Foundation (NKF).
Exclusion Criteria:
- Immobility with inability to go out and participate in training course
- History of a fracture or of a stroke provided the event has occurred in the last 3 months
- Presence of a physical or mental disorder that has led to a set-up or to a planned set-up for a statutory care
- Severe dementia
- Severe disorder of speech or comprehension
- Disease that rules out participation during the intervention period or that would deteriorate as a result of type of intervention (e.g. absorptive hypercalciuria, nephrocalcinosis, calcium containing renal calculi or hypophosphataemia)
- Hypersensitivity (allergy) to Alfacalcidol, groundnuts, groundnut oil or Soya
- Vitamin-D hypersensitivity or -intoxication
- Simultaneous intake of vitamin D and its derivatives.
- Participation in any other clinical trial, that is still ongoing or has been completed less than 3 months prior date of intended inclusion
- Substitution of more than 500 mg calcium per day
- Planned medical therapy during the period of intervention that requires long-term suspension of intervention.
- Presence of hypercapnia of over 2.6mmol/l, calcium x phosphate product of over 3.7 (mmol/l)2 and alkalosis with venous blood-pH- reading of over 7.44 (milk-alkali-syndrome, Burnett syndrome)
- Hypercalcaemia (e.g. as a result of hyperparathyroidism, an overdose of vitamin D, paraneoplastic syndrome, osseous metastases, sarcoidosis, Boeck´s disease, osteoporosis induced by immobilisation) or hypermagnesemia according to normative values of the engaged laboratory
- Hereditary fructose intolerance
- Commitment into an institution

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00483275
Germany | |
Klinik für Altersmedizin und Frührehabilitation, Marienhospital, Ruhr-Universität Bochum | |
Herne, NRW, Germany, 44627 |
Principal Investigator: | Prof. Dr. med. Ludger Pientka, MD, MPH | Klinik für Altersmedizin und Frührehabilitation, Marienhospital Herne, Ruhr-Universität Bochum |
ClinicalTrials.gov Identifier: | NCT00483275 History of Changes |
Other Study ID Numbers: |
GER-001-SP EudraCT 2006-006205-83 |
First Posted: | June 7, 2007 Key Record Dates |
Last Update Posted: | July 21, 2011 |
Last Verified: | July 2011 |
Keywords provided by Ruhr University of Bochum:
Accidental Falls Accident Prevention Patient Education Exercise Training Alfacalcidol |
Additional relevant MeSH terms:
Renal Insufficiency Renal Insufficiency, Chronic Kidney Diseases Urologic Diseases Alfacalcidol Hydroxycholecalciferols |
Bone Density Conservation Agents Physiological Effects of Drugs Vitamins Micronutrients Growth Substances |